MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) and spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) unveil their financial forecasts for the first half of 2024, along with business updates.
MedBot anticipates a significant year-on-year (YOY) revenue increase of 103% to 108%, attributed to robust domestic demand and international commercialization of its Toumai endoscopic surgery robot. Additionally, increased sales volumes of its orthopedic surgery robot SkyWalker and the successful market launch of the R-ONE vascular intervention robot have contributed to this growth.
CardioFlow, on the other hand, forecasts its revenues to be within the range of RMB 215 million to RMB 225 million (USD 29.5 million to USD 31 million), marking a 22% to 28% YOY increase. Key growth drivers include the company’s transcatheter aortic valve implantation (TAVI) product, which has been introduced to 50 hospitals in China, expanding the total to over 600. The AnchorMan left atrial appendage occluder system and its guiding system have been procured online in nearly 20 provinces and are in the process of being listed in over 10 provinces. Furthermore, the VitaFlow Liberty transcatheter aortic valve and delivery system, along with the Alwide Plus balloon dilation catheter, have experienced rapid international adoption.- Flcube.com
